AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3524181 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31586969 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time ASD
Number of subjects: 56
Study 31586969 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent ASD
Number of subjects: 56
Study 31586969 — intervention group
Group type: COMPARATOR
Intervention: Both groups (First-time and Recurrent ASD)
Number of subjects: 56
Study 28589472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + saline solution (SSL) for 7 days
Number of subjects: 72
Study 28589472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine (CHX) gel for 7 days
Number of subjects: 72
Study 28589472 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX gel for 7 days
Number of subjects: 72
Study 28589472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + saline solution (SSL) for 14 days
Number of subjects: 72
Study 28589472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine (CHX) gel for 14 days
Number of subjects: 72
Study 28589472 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX gel for 14 days
Number of subjects: 72
Study 27756349 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal Guided Self Help, in addition to usual care
Number of subjects: 0
Study 27756349 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24722260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg over 10 minutes followed by a continuous infusion of 0.5 μg/kg/h throughout surgery)
Number of subjects: 66
Study 24722260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 66
Study 24722260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 66
Study 22229535 — intervention group
Group type: EXPERIMENTAL
Intervention: Male students
Number of subjects: 1833
Study 22229535 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who began drinking earlier in life
Number of subjects: 1833
Study 22229535 — intervention group
Group type: COMPARATOR
Intervention: Living in on-campus housing
Number of subjects: 1833
Study 20076850 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release AZD0837 150mg bid
Number of subjects: 250
Study 20076850 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release AZD0837 350mg bid
Number of subjects: 250
Study 20076850 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin
Number of subjects: 250
Study 20076850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AZD0837 groups
Number of subjects: 250
Study 20076850 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 250
Study 18782078 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RTCT) with 5-FU-based treatment
Number of subjects: 0
Study 18782078 — intervention group
Group type: COMPARATOR
Intervention: Preoperative short-course RT alone (5 x 5 Gy)
Number of subjects: 0
Study 18782078 — intervention group
Group type: COMPARATOR
Intervention: Postoperative RTCT
Number of subjects: 0
Study 15821396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early exclusive breastfeeding (EBF)
Number of subjects: 4495
Study 15821396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mixed breastfeeding
Number of subjects: 4495
Study 15821396 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant breastfeeding
Number of subjects: 4495
Study 12424553 — intervention group
Group type: EXPERIMENTAL
Intervention: LI 160 (600 mg/day)
Number of subjects: 151
Study 12424553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12424553 — intervention group
Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 151
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared egg donation programme (donors)
Number of subjects: 1329
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared egg donation programme (recipients)
Number of subjects: 1329
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Donors >35 years
Number of subjects: 1329
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients >50 years
Number of subjects: 1329
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipients >45 years
Number of subjects: 1329
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection treatment for severe male factor infertility
Number of subjects: 1329
Study 10527975 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis (in both groups)
Number of subjects: 1329
Study 8577017 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) at day 1, n = 4
Number of subjects: 9
Study 8577017 — intervention group
Group type: COMPARATOR
Intervention: Delayed parenteral nutrition (PN) at day 5, n = 5
Number of subjects: 9
Study 1832232 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser thermal recanalization
Number of subjects: 0
Study 1832232 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional recanalization
Number of subjects: 0
Study 1832232 — intervention group
Group type: COMPARATOR
Intervention: Conventional guide wire
Number of subjects: 0
Study 1832232 — intervention group
Group type: COMPARATOR
Intervention: Hybrid laser probe
Number of subjects: 0
Study 7050403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 0
Study 7050403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31950384 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy (SEGT) combined with oncologic treatment (BRBC)
Number of subjects: 3327
Study 31950384 — intervention group
Group type: COMPARATOR
Intervention: Oncologic treatment only (OT)
Number of subjects: 3327
Study 30771790 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 600 mg/d for 3 months
Number of subjects: 50
Study 28166118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 49
Study 28166118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 49
Study 28166118 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise Controls (CONT)
Number of subjects: 49
Study 27125731 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients expecting improvement/stabilisation (56%, N = 380)
Number of subjects: 678
Study 27125731 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients expecting deterioration (8%, N = 55)
Number of subjects: 678
Study 27125731 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not knowing what to expect (21%, N = 144)
Number of subjects: 678
Study 24140820 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant dimension primes in rule-based (RB) category learning
Number of subjects: 0
Study 24140820 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant dimension primes in information-integration (II) category learning
Number of subjects: 0
Study 21967242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic and antihypertensive agents)
Number of subjects: 108
Study 21967242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents)
Number of subjects: 108
Study 21967242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and vitamin E)
Number of subjects: 108
Study 21967242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (hypoglycemic, antihypertensive and lipid-lowering agents, and compound salvia tablets)
Number of subjects: 108
Study 21967242 — intervention group
Group type: COMPARATOR
Intervention: Control group (83 healthy subjects)
Number of subjects: 108
Study 21967242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 108
Study 19408302 — intervention group
Group type: COMPARATOR
Intervention: No delay (<5 days)
Number of subjects: 3767
Study 19408302 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay >or=5 days
Number of subjects: 3767
Study 19408302 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay >or=7 days
Number of subjects: 3767
Study 19408302 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting of positive samples
Number of subjects: 3767
Study 19408302 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples stored at room temperature
Number of subjects: 3767
Study 17534979 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase before ACT
Number of subjects: 24
Study 17534979 — intervention group
Group type: COMPARATOR
Intervention: rhDNase after ACT
Number of subjects: 24
Study 15469774 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705
Study 15469774 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (pooled doses)
Number of subjects: 7705
Study 11237229 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin
Number of subjects: 56
Study 11237229 — intervention group
Group type: COMPARATOR
Intervention: cephalothin plus netilmicin
Number of subjects: 56
Study 9840853 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/kg of 0.35% lidocaine with 1:1,000,000 epinephrine
Number of subjects: 0
Study 9840853 — intervention group
Group type: COMPARATOR
Intervention: 5 mL/kg of saline with 1:1,000,000 epinephrine
Number of subjects: 0
Study 8018041 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with probable AD
Number of subjects: 10
Study 8018041 — intervention group
Group type: COMPARATOR
Intervention: Healthy age- and education-matched controls
Number of subjects: 10
Study 2684698 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (2 mg)
Number of subjects: 80
Study 2684698 — intervention group
Group type: COMPARATOR
Intervention: PGE2 tablet (3 mg)
Number of subjects: 80
Study 31808352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandal insole group (SI; n=34)
Number of subjects: 66
Study 31808352 — intervention group
Group type: COMPARATOR
Intervention: Plain sandal group (PS; n=32)
Number of subjects: 66
Study 30807822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung dose ≥800 cGy
Number of subjects: 127
Study 30807822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung dose <800 cGy
Number of subjects: 127
Study 30807822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral fields
Number of subjects: 127
Study 25257861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous elemental iron (40 mg) administered at all three hemodialysis sessions in the first week (IW1 group: n=57)
Number of subjects: 110
Study 25257861 — intervention group
Group type: COMPARATOR
Intervention: Intravenous elemental iron (40 mg) administered in the third week (IW3 group: n=53)
Number of subjects: 110
Study 22717454 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (0.5 mg/kg SC, n=4)
Number of subjects: 43
Study 22717454 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (1.5 mg/kg SC, n=5)
Number of subjects: 43
Study 22717454 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (3.0 mg/kg SC, n=4)
Number of subjects: 43
Study 22717454 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (4.0 mg/kg IV, n=5)
Number of subjects: 43
Study 22717454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 43
Study 22717454 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrolizumab (all doses in MD stage)
Number of subjects: 43
Study 21375410 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home wireless glucose monitor and transmitter (experimental group, n=50)
Number of subjects: 100
Study 21375410 — intervention group
Group type: COMPARATOR
Intervention: Conventional arrangement (control group, n=50)
Number of subjects: 100
Study 18178369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine (1mL of morphine compounded at 10mg/mL in pluronic lecithin organogel applied to the wrist)
Number of subjects: 5
Study 18178369 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine (1mL of 3mg/mL)
Number of subjects: 5
Study 18178369 — intervention group
Group type: COMPARATOR
Intervention: Topical drug-free PLO base (1mL)
Number of subjects: 5
Study 16338812 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum Data Set‐Home Care (MDS‐HC)
Number of subjects: 925
Study 16338812 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 925
Study 12556011 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF and antibiotic therapy (n=8)
Number of subjects: 15
Study 12556011 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (n=7)
Number of subjects: 15
Study 12556011 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 15
Study 10951246 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident solar keratoses diagnosed during 12 months follow-up
Number of subjects: 96
Study 10951246 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of solar keratoses
Number of subjects: 96
Study 10951246 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of prevalent solar keratoses
Number of subjects: 96
Study 10951246 — intervention group
Group type: EXPERIMENTAL
Intervention: Net increase in solar keratosis numbers in men
Number of subjects: 96
Study 10951246 — intervention group
Group type: EXPERIMENTAL
Intervention: Net reduction in solar keratosis numbers in women
Number of subjects: 96
Study 10951246 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood of developing additional solar keratoses
Number of subjects: 96
Study 8849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative spondylodiscitis (POD) group
Number of subjects: 875
Study 8849475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 875
Study 8849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with antibiotics for POD
Number of subjects: 875
Study 8849475 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) during acute phase
Number of subjects: 875
Study 8849475 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI during subacute phase
Number of subjects: 875
Study 8849475 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI three months after treatment
Number of subjects: 875
Study 1501004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prealbumin (PA)
Number of subjects: 10
Study 1501004 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (Alb)
Number of subjects: 10
Study 1501004 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation (energy balance and protein intake)
Number of subjects: 10
Study 7006558 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 7006558 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline hydrochloride
Number of subjects: 0
Study 7006558 — intervention group
Group type: COMPARATOR
Intervention: Combination of amitriptyline and IPT
Number of subjects: 0
Study 31278280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 100 mg
Number of subjects: 0
Study 31278280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 300 mg
Number of subjects: 0
Study 31278280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg
Number of subjects: 0
Study 31278280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28395124 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 246
Study 28395124 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC)
Number of subjects: 246
Study 25497362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for GAD
Number of subjects: 0
Study 25497362 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study 24037918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 0
Study 24037918 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 0
Study 20031380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut diet (30 g/day of raw nuts: 15 g walnuts, 7.5 g almonds, 7.5 g hazelnuts)
Number of subjects: 50
Study 20031380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut diet (30 g/day of raw nuts)
Number of subjects: 50
Study 20031380 — intervention group
Group type: COMPARATOR
Intervention: Control diet (without nuts)
Number of subjects: 50
Study 19572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate infusion (2 g)
Number of subjects: 20
Study 19572078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 20
Study 17295799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with tablets of HDM extract (n = 55)
Number of subjects: 111
Study 17295799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 56)
Number of subjects: 111
Study 15333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of (70)Zn or (67)Zn
Number of subjects: 5
Study 15333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Zn concentration
Number of subjects: 5
Study 12226038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output nebulizer
Number of subjects: 20
Study 12226038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-output nebulizer
Number of subjects: 20
Study 9575624 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemnol
Number of subjects: 60
Study 9575624 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate
Number of subjects: 60
Study 7867675 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195 250 mg
Number of subjects: 12
Study 7867675 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195 100 mg
Number of subjects: 12
Study 7867675 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY x 7195 500 mg
Number of subjects: 12
Study 7867675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2670019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (ESTRADERM TTS‐50), 50 micrograms/day
Number of subjects: 34
Study 2670019 — intervention group
Group type: COMPARATOR
Intervention: Control group (medroxyprogesterone 10 mg/day for 12 days)
Number of subjects: 34
Study 876804 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ear presentation of pure tones
Number of subjects: 20
Study 876804 — intervention group
Group type: COMPARATOR
Intervention: Right ear presentation of pure tones
Number of subjects: 20
Study 30826757 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day communication skills training (CST)
Number of subjects: 172
Study 30826757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CST before post-test)
Number of subjects: 172
Study 28119433 — intervention group
Group type: EXPERIMENTAL
Intervention: AURAS‐AF software tool for automated risk assessment and reminders for OAC treatment.
Number of subjects: 47
Study 28119433 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 47
Study 28119433 — intervention group
Group type: EXPERIMENTAL
Intervention: AURAS‐AF software tool for automated risk assessment.
Number of subjects: 47
Study 26153191 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy, performed in three sessions on alternate days for 45-90 minutes over four months.
Number of subjects: 60
Study 26153191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 60
Study 26153191 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mean depression level at post treatment between both groups.
Number of subjects: 60
Study 24350936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 654
Study 24350936 — intervention group
Group type: COMPARATOR
Intervention: Control (other oral antidiabetic agents)
Number of subjects: 654
Study 24350936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 654
Study 21808751 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine ODT (10 to 20 mg, once daily)
Number of subjects: 23
Study 21808751 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine SOT (10 to 20 mg, once daily)
Number of subjects: 23
Study 21808751 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine ODT
Number of subjects: 23
Study 21808751 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine SOT
Number of subjects: 23
Study 19558484 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for nursing staff combined with consultation with a nurse specialist (RN level)
Number of subjects: 241
Study 19558484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 241
Study 17880439 — intervention group
Group type: COMPARATOR
Intervention: rFVIIa (NovoSeven)
Number of subjects: 0
Study 17880439 — intervention group
Group type: COMPARATOR
Intervention: VII25
Number of subjects: 0
Study 17880439 — intervention group
Group type: COMPARATOR
Intervention: rFVIIa and VII25
Number of subjects: 0
Study 15111514 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 231
Study 15111514 — intervention group
Group type: COMPARATOR
Intervention: Human Soluble Insulin (HI)
Number of subjects: 231
Study 15111514 — intervention group
Group type: COMPARATOR
Intervention: Human Premix Insulin (MIX)
Number of subjects: 231
Study 12421890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount-high-intensity exercise (jogging 20 mi/week at 65-80% peak oxygen consumption)
Number of subjects: 111
Study 12421890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount-high-intensity exercise (jogging 12 mi/week at 65-80% peak oxygen consumption)
Number of subjects: 111
Study 12421890 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amount-moderate-intensity exercise (walking 12 mi/week at 40-55% peak oxygen consumption)
Number of subjects: 111
Study 12421890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 9612831 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated counseling (RC)
Number of subjects: 861
Study 9612831 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous antismoking advice by the GP
Number of subjects: 861